For the Inventor, By the Inventor

Enter assignee name

Lausanne, Switzerland

Debiopharm S.a.

USPTO Granted Patents = 28

CIPO Patents = 3

EPO Patents = 6

Trademarks = 3

Forward Citations = 737

Loading Chart...

Loading Chart...

63 inventors (with patents filed for the assignee):

Piero Orsolini (7 out of 17 patents)

Rolland-Yves Mauvernay (6 out of 10 patents)

Houssam Ibrahim (5 out of 5 patents)

4. Manfred Mutter (4 out of 5 patents)

5. Roland M Wenger (4 out of 17 patents)

6. Romano Deghenghi (3 out of 4 patents)

7. Saumitra Sengupta (2 out of 12 patents)

8. Grégoire Vuagniaux (2 out of 8 patents)

9. Maximilien Murone (2 out of 8 patents)

10. Andrès Mc Allister (2 out of 2 patents)

11. Shankar Jayaram Shetty (2 out of 2 patents)

12. Henri Pourrat (2 out of 2 patents)

13. Christine Deuschel (2 out of 2 patents)

14. Alain Poncin (2 out of 2 patents)

15. Anne Bokman (2 out of 2 patents)

28 patents: Sort by Forward Citations

1. 8962637 - Bicyclic compounds and their uses as dual c-SRC/JAK inhibitors (2015-02-24),

2. 8911934 - Near full-genome assay of HCV drug resistance (2014-12-16),

3. 8450281 - Non-immunosuppressive cyclosporin for treatment of Ullrich congenital muscular dystrophy (2013-05-28),

4. 8440679 - Bicyclic compounds and their uses as dual c-SRC / JAK inhibitors (2013-05-14),

5. 8211940 - Oxaliplatin active substance with a very low content of oxalic acid (2012-07-03),

6. RE40987 - Cyclosporin with improved activity profile (2009-11-16),

7. 7070796 - Pharmaceutically stable oxaliplatinum preparation for parenteral administration (2006-07-04),

8. 7012072 - Pharmaceutical oxaliplatinum preparation for parenteral administration and method for obtaining same (2006-03-14),

9. 6995139 - Cyclic undecapeptide pro-drugs and uses thereof (2006-02-07),

10. 6989438 - Process for the purification of EPI-HNE proteins (2006-01-24),

11. 6927208 - Cyclosporin with improved activity profile (2005-08-09),

12. 6866857 - Oxalipatinum preparation packaging (2005-03-15),

13. 6814982 - Suspension of an EPI-HNE protein, process of preparation thereof, dry powder aerosol derived therefrom, pharmaceutical compositions containing said suspension or aerosol, and their uses (2004-11-09),

14. 6790935 - Cyclosporin derivatives and method for the production of said derivatives (2004-09-14),

15. 6528524 - Pharmaceutical compositions containing cinchonine dichlorhydrate (2003-03-04),

Debiopharm is an independent, privately-owned biopharmaceutical company based in Switzerland. Since its establishment in 1979, the company has been dedicated to developing innovative therapies that address unmet medical needs. Debiopharm focuses on drug development in oncology, infectious diseases, gynecology, and other areas with high unmet medical needs. The company's goal is to improve patients' quality of life by delivering effective and safe treatments. Debiopharm collaborates with academic institutions, research centers, and other pharmaceutical companies to advance its pipeline of drug candidates. With a strong commitment to research and development, Debiopharm is actively engaged in discovering and developing new therapeutic solutions.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 2 2025

28 Patents

#12 in Lausanne

#448 in Switzerland

#22,535 in the World

Lausanne, Switzerland

Debiopharm S.a.

Forward Citations = 737

63 inventors:

Piero Orsolini (7 out of 17 patents)

Rolland-Yves Mauvernay (6 out of 10 patents)

Houssam Ibrahim (5 out of 5 patents)

4. Manfred Mutter (4 out of 5 patents)

5. Roland M Wenger (4 out of 17 patents)

Please report any incorrect information to support@idiyas.com

Loading…